Revive Therapeutics (RVVTF) Moves a Step Closer to FDA Verdict for Its Novel Covid...
Two Binary Events Directly Ahead.
As in Months Away, not Years. Share Price up 76% During April.
As we stated earlier, Revive Therapeutics (RVVTF)...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
TORONTO, April 11, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company...
Could Bucillamine be the Key to Preventing Lockdowns in Places Like North Korea?
Revive Therapeutics Nears FDA-EUA Approval or Non-approval, for Bucillamine its Novel Anti-inflammatory and Antioxidant. Bucillamine 'Boosts' Glutathione, a Natural Substance Found in Virtually all...
Revive’s Quarterly Report, Discussion, and a Video!
With 5,000 hospitalizations reported daily (150,000 a month), contracting Covid is not something to be taken lightly - after you get it.
Unless of...
Ehave’s Mobile Ketamine Clinic, Rolling into Town.
Longer term, Ehave's (EHVVF) performance has been a quite a disappointment. Investors grew impatient for the launch of one of the most significant advances...
Latest article
Fairchild Gold Corp., Presenting at Palm Beach Investor Roadshow.
Vancouver, British Columbia and Las Vegas, Nevada--(Institutional Analyst - April 8th, 2026) - Fairchild Gold Corp. (TSXV: FAIR) (FSE: Y4Y) (OTCQB: FCHDF) ("Fairchild" or the "Company"),...
Precious Metals Analyst | Mark Reichman | Noble Capital
Mark Reichman
Senior Research Analyst, Industrials and Basic Industries
BIO
Mark joined Noble as a senior research analyst with coverage responsibility in the Industrials and Basic Industries...
